Clinical trials: Non Alcoholic Fatty Liver
Obesity
Clinical Efficacy and Safety of a Laparoscopic Sleeve Gastrectomy in Obese Patients
This study aim to evaluate the clinical efficacy and safety after laparoscopic sleeve gastrectomy in patients with obesity. 300 patients with obesity and 49 healthy individuals with normal BMI were enrolled.
- Trial name
- NCT04548232
- Testing
- Laparoscopic sleeve gastrectomy
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital
Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis
Genetic Studies of Non-Alcoholic Fatty Liver Disease
Background: Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions.
- Conditions
- Non-Alcoholic Steato-Hepatitis, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT01629095
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver
CT Liver Fat Fraction Quantification
Our aim is to develop an AI based tool to use ultra-low dose CT in two separate energy levels using a single-energy CT machine to quantify liver fat in individuals at risk for having non-alcoholic fatty liver disease (NAFLD)…
- Trial name
- NCT05676177
- Testing
- Ultra Low Dose CT, Fat quantification MRI
- Where
- Israel
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Obstructive Sleep Apnea, Non-alcoholic Fatty Liver Disease
Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease
To study the frequency of obstructive sleep apnea (OSA) and continuous positive airway pressure (CPAP) treatment response in patients with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT02728765
- Testing
- Continuous positive airway pressure (CPAP)
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- Chinese University of Hong Kong
NASH, Cirrhosis, Liver
A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical…
- Trial name
- NCT05500222
- Testing
- Resmetirom
- Where
- 141 sites in United States, Belgium and 7 more
- Volunteers
- 845 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Liver Fat
Diet, Immunometabolism and Non-alcoholic Fatty Liver Disease
This study will assess the impact of 8-hour time restricted eating (8 hours of eating, 16 hours fasting) combined with a Mediterranean diet on metabolism and inflammation in adults with non-alcoholic fatty liver disease (NAFLD).
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Fat, Obesity, Inflammation
- Trial name
- NCT05968378
- Testing
- Standard healthy eating advice, eTRE plus Mediterranean diet
- Where
- Ireland
- Volunteers
- 60 people
- Sponsor
- University College Dublin
Fatty Liver, Nonalcoholic Steatohepatitis
Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
This study will evaluate the effectiveness of pioglitazone, a new diabetes medicine, on decreasing insulin resistance and improving liver disease in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT00013598
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type II Diabetes, Nonalcoholic Fatty Liver
Fatty Liver Study in Patients With Type II Diabetes
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with…
- Trial name
- NCT02365233
- Testing
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Fatty Liver Disease, Fatty Liver
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
Objective of this study is to determine the clinical benefits of itopride in improvement of MAFLD
- Trial name
- MAFLD (NCT05966025)
- Testing
- Itopride, conventional therapy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- October 6 University
NAFLD
Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
The investigators will conduct a proof-of-principle 4-weeks low-calorie diet (LCD) intervention study in low birth weight (LBW) subjects and normal birth weight (NBW) controls with documented (MR scan) liver fat content equal to…
- Trial name
- NCT05842850
- Testing
- Caloric restriction intervention, No intervention
- Where
- 2 sites in Denmark
- Volunteers
- 8 people
- Sponsor
- Steno Diabetes Center Copenhagen
Nash
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients
Human genetic studies have shown that loss of function (LOF) mutations in HSD17β13 gene have a protective effect on the progression of alcohol-related and non-alcohol-related liver diseases, such as NASH, without significant…
- Trial name
- NCT06322628
- Testing
- VSA006
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Visirna Therapeutics HK Limited
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome
The goal of this clinical trial is to investigate the use of ultra-high performance liquid chromatography-mass spectrometry for metabolomics and proteomics research in patients with Polycystic Ovary Syndrome (PCOS) and…
- Trial name
- NCT06256289
- Testing
- Canagliflozin 100mg Tab, Metformin Hydrochloride
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Ping Li,MD
Cardiovascular Diseases
Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers
The risk of cardiovascular disease is determined by the complex interplay between an individual's genetic make-up, lifestyle, and the environment.
- Trial name
- CADBIO (NCT03038750)
- Testing
- Eligibility and lifestyle restrictions check., Medical history, demographic and lifestyle factors, Anthropometric measurements: height, weight, and body fat
- Where
- United Kingdom
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis
Human microbiota is the set of microorganisms that, in a symbiotic way, coexist and develop in the different surfaces (skin and mucous membranes) of the human body.
- Trial name
- FMT-NASH (NCT03803540)
- Testing
- Fecal Microbiota Transplantation
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Puerta de Hierro University Hospital
Non-alcoholic Fatty Liver Disease
Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Liver Transplant Recipients
The purpose of this study is is to use non-invasive diagnostic tests, Fibroscan and a simple blood test, to diagnose NASH in patients who undergo liver transplantation.
- Trial name
- NCT03128918
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Obesity, Dyslipidemia
Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk
The rise in high fructose corn syrup (HFCS) consumption over the past 40 years since its introduction as a popular sweetener in the United States has led to much concern regarding its contribution to the rise in obesity (1)…
- Conditions
- Obesity, Dyslipidemia, Prediabetes, Dysglycemia
- Trial name
- NCT02702479
- Testing
- High Fructose Corn Syrup, Sucrose
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Non-Alcoholic Steatohepatitis (NASH)
Phase 2b Study in NASH to Assess IVA337
Non-alcoholic steatohepatitis, abbreviated as NASH, is a chronic liver disease that may progress to cirrhosis. The disease is mostly associated with obesity and type 2 diabetes mellitus, or insulin resistance and is very common.
- Trial name
- NATIVE (NCT03008070)
- Testing
- IVA337
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 247 people
- Sponsor
- Inventiva Pharma
Nonalcoholic Fatty Liver Disease
Effect of Mediterranean Diet in Obese Adolescents With Nonalcoholic Fatty Liver Disease
The aim of this study was to evaluate the effects of mediterranean and low-fat diet on hepatic fat, inflammation markers and oxidative stress in adolescents with nonalcoholic fatty liver disease.
- Trial name
- NCT04845373
- Testing
- Mediterranean diet, Control diet: Low fat diet
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Gazi University
Non-alcoholic Fatty-liver Disease
Effects of Dietary Fructose Reduction in Children With Hepatic Steatosis
Primary Objectives: 1. To determine whether a 4 week reduction in dietary fructose intake improves hepatic steatosis in overweight children who have a baseline high fructose consumption and hepatic steatosis. 2.
- Trial name
- Sweet Bev (NCT01188083)
- Testing
- Fructose Drink, Glucose Drink
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.